Electrochemotherapy: Progress and Prospects.

Abstract : Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Type de document :
Article dans une revue
Current Pharmaceutical Design, Bentham Science Publishers, 2012, epub ahead of print
Liste complète des métadonnées

Littérature citée [38 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00680356
Contributeur : Marie-Pierre Rols <>
Soumis le : lundi 19 mars 2012 - 11:57:28
Dernière modification le : jeudi 11 janvier 2018 - 06:15:31
Document(s) archivé(s) le : mercredi 14 décembre 2016 - 17:14:44

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

  • HAL Id : inserm-00680356, version 1
  • PUBMED : 22397731

Collections

Citation

Jean-Michel Escoffre, Marie-Pierre Rols. Electrochemotherapy: Progress and Prospects.. Current Pharmaceutical Design, Bentham Science Publishers, 2012, epub ahead of print. 〈inserm-00680356〉

Partager

Métriques

Consultations de la notice

138